Duchenne Muscular Dystrophy (DMD) Therapeutic Drug Market Outlook 2026-2037

The global Duchenne muscular dystrophy (DMD) therapeutic drug market was valued at USD 32.91 billion in 2025 and is projected to reach USD 66.56 billion by 2037, rising at a CAGR of 5.8% (2026-2037). In 2026, the market size is expected to be USD 35.59 billion.

Report Scope

Overview of the market, value chain, and ecosystem
Research methodology, analytical approach, and data validation process
Executive summary highlighting key findings, market dynamics, and insights
Analysis of growth drivers, constraints, opportunities, trends, and regulatory impact
Market outlook with forward-looking projections and scenario-based forecasting
Competitive white space and untapped opportunity identification
Assessment of risks, challenges, and uncertainties
SWOT, PESTLE, Porter’s Five Forces, and Root Cause Analysis frameworks
Technological advancements and technology maturity mapping
Tracking of recent developments, product launches, and strategic initiatives
Regional demand analysis and comparative geographic positioning
Strategic segment analysis and demand trends
Competitive landscape, market share distribution, and investor-focused benchmarking
Impact of global economic conditions on market performance

1. An Outline of the Global Duchenne Muscular Dystrophy (DMD) Therapeutic Drug Market

1.1. Market Definition and Segmentation
1.2. Study Assumptions and Abbreviations

2. Research Methodology & Approach

2.1. Primary Research
2.2. Secondary Research
2.3. Data Triangulation
2.4. SPSS Methodology

3. Executive Summary4. Growth Drivers5. Major Roadblocks6. Opportunities7. Prevalent Trends8. Government Regulation9. Growth Outlook10. Competitive White Space Analysis - Identifying Untapped Market Gaps11. Risk Overview12. SWOT13. Technological Advancement14. Technology Maturity Matrix for Global Duchenne Muscular Dystrophy (DMD) Therapeutic Drug Market15. Recent News16. Regional Demand17. Global Duchenne Muscular Dystrophy (DMD) Therapeutic Drug Market by Geography - Strategic Comparative Analysis18. Strategic Segment Analysis: Global Duchenne Muscular Dystrophy (DMD) Therapeutic Drug Market19. Global Duchenne Muscular Dystrophy (DMD) Therapeutic Drug Demand Trends (2026-2037)20. Root Cause Analysis (RCA) for discovering problems of the Global Duchenne Muscular Dystrophy (DMD) Therapeutic Drug Market21. Porter Five Forces22. PESTLE23. Comparative Positioning24. Global Duchenne Muscular Dystrophy (DMD) Therapeutic Drug Market - Key Player Analysis (2037)25. Competitive Landscape: Key Suppliers/Players26. Competitive Model: A Detailed Inside View for Investors

27. Company Market Share, 2037 (%)

27.1. Business Profile of Key Enterprise
27.1.1. Sarepta Therapeutics
27.1.2. PTC Therapeutics
27.1.3. Pfizer
27.1.4. BioMarin
27.1.5. Bristol-Myers Squibb
27.1.6. Eli Lilly and Company
27.1.7. Santhera Pharmaceuticals
27.1.8. NS Pharma
27.1.9. Aurobindo Pharma
27.1.10. Capricor Therapeutics
27.1.11. Catalyst Pharmaceuticals
27.1.12. Italfarmaco
27.1.13. Summit Therapeutics
27.1.14. Catbasis Pharmaceuticals
27.1.15. CureDuchenne

28. Global Duchenne Muscular Dystrophy (DMD) Therapeutic Drug Market Outlook

28.1. Market Overview
28.1.1. Market Revenue by Value (USD Million), Volume (Thousand Tons), and Compound Annual Growth Rate (CAGR)
28.2. Duchenne Muscular Dystrophy (DMD) Therapeutic Drug Market Segmentation Analysis (2026-2037)
28.2.1. By Drug Class
28.2.1.1. ~Corticosteroids, Market Value (USD Million), and CAGR, 2026-2037F
28.2.1.2. ~Exon-skipping Drugs, Market Value (USD Million), and CAGR, 2026-2037F
28.2.1.3. ~Gene Therapy, Market Value (USD Million), and CAGR, 2026-2037F
28.2.1.4. ~Others, Market Value (USD Million), and CAGR, 2026-2037F
28.2.2. By Distribution Channel
28.2.2.1. Hospital Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
28.2.2.2. Retail Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
28.2.2.3. Online Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
28.2.2.4. Specialized Clinics, Market Value (USD Million), and CAGR, 2026-2037F
28.2.3. By Treatment Approach
28.2.3.1. Molecular Biological Therapy, Market Value (USD Million), and CAGR, 2026-2037F
28.2.3.2. Steroid Therapy, Market Value (USD Million), and CAGR, 2026-2037F
28.2.3.3. Anti-inflammatory and Immunomodulatory Drugs, Market Value (USD Million), and CAGR, 2026-2037F
28.2.3.4. Myostatin Inhibitors, Market Value (USD Million), and CAGR, 2026-2037F
28.2.3.5. Cell Biological Therapy, Market Value (USD Million), and CAGR, 2026-2037F
28.2.4. Regional Synopsis, Value (USD Million), 2026-2037
28.2.4.1. North America Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
28.2.4.2. Europe Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
28.2.4.3. Asia Pacific Excluding Japan Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
28.2.4.4. Japan Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
28.2.4.5. Latin America Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
28.2.4.6. Middle East and Africa Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F

29. North America Market

29.1. Overview
29.1.1. Market Value (USD Million), Current and Future Projections, 2026-2037
29.1.2. Increment $ Opportunity Assessment, 2026-2037
29.2. Segmentation (USD million), 2026-2037, By
29.2.1. By Drug Class
29.2.1.1. ~Corticosteroids, Market Value (USD Million), and CAGR, 2026-2037F
29.2.1.2. ~Exon-skipping Drugs, Market Value (USD Million), and CAGR, 2026-2037F
29.2.1.3. ~Gene Therapy, Market Value (USD Million), and CAGR, 2026-2037F
29.2.1.4. ~Others, Market Value (USD Million), and CAGR, 2026-2037F
29.2.2. By Distribution Channel
29.2.2.1. Hospital Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
29.2.2.2. Retail Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
29.2.2.3. Online Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
29.2.2.4. Specialised Clinics, Market Value (USD Million), and CAGR, 2026-2037F
29.2.3. By Treatment Approach
29.2.3.1. Molecular Biological Therapy, Market Value (USD Million), and CAGR, 2026-2037F
29.2.3.2. Steroid Therapy, Market Value (USD Million), and CAGR, 2026-2037F
29.2.3.3. Anti-inflammatory and Immunomodulatory Drugs, Market Value (USD Million), and CAGR, 2026-2037F
29.2.3.4. Myostatin Inhibitors, Market Value (USD Million), and CAGR, 2026-2037F
29.2.3.5. Cell Biological Therapy, Market Value (USD Million), and CAGR, 2026-2037F
29.2.4. Country Level Analysis, Value (USD Million)
29.2.4.1. U.S. Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
29.2.4.2. Canada Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F

30. Europe Market

30.1. Overview
30.1.1. Market Value (USD Million), Current and Future Projections, 2026-2037
30.1.2. Increment $ Opportunity Assessment, 2026-2037
30.2. Segmentation (USD million), 2026-2037, By
30.2.1. By Drug Class
30.2.1.1. ~Corticosteroids, Market Value (USD Million), and CAGR, 2026-2037F
30.2.1.2. ~Exon-skipping Drugs, Market Value (USD Million), and CAGR, 2026-2037F
30.2.1.3. ~Gene Therapy, Market Value (USD Million), and CAGR, 2026-2037F
30.2.1.4. ~Others, Market Value (USD Million), and CAGR, 2026-2037F
30.2.2. By Distribution Channel
30.2.2.1. Hospital Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
30.2.2.2. Retail Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
30.2.2.3. Online Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
30.2.2.4. Specialised Clinics, Market Value (USD Million), and CAGR, 2026-2037F
30.2.3. By Treatment Approach
30.2.3.1. Molecular Biological Therapy, Market Value (USD Million), and CAGR, 2026-2037F
30.2.3.2. Steroid Therapy, Market Value (USD Million), and CAGR, 2026-2037F
30.2.3.3. Anti-inflammatory and Immunomodulatory Drugs, Market Value (USD Million), and CAGR, 2026-2037F
30.2.3.4. Myostatin Inhibitors, Market Value (USD Million), and CAGR, 2026-2037F
30.2.3.5. Cell Biological Therapy, Market Value (USD Million), and CAGR, 2026-2037F
30.2.4. Country Level Analysis, Value (USD Million)
30.2.4.1. UK Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
30.2.4.2. Germany Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
30.2.4.3. France Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
30.2.4.4. Italy Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
30.2.4.5. Spain Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
30.2.4.6. Netherlands Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
30.2.4.7. Russia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
30.2.4.8. Switzerland Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
30.2.4.9. Poland Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
30.2.4.10. Belgium Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
30.2.4.11. Rest of Europe Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F

31. Asia Pacific Excluding Japan Market

31.1. Overview
31.1.1. Market Value (USD Million), Current and Future Projections, 2026-2037
31.1.2. Increment $ Opportunity Assessment, 2026-2037
31.2. Segmentation (USD million), 2026-2037,
31.2.1. By Drug Class
31.2.1.1. ~Corticosteroids, Market Value (USD Million), and CAGR, 2026-2037F
31.2.1.2. ~Exon-skipping Drugs, Market Value (USD Million), and CAGR, 2026-2037F
31.2.1.3. ~Online Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
31.2.1.4. ~Specialized Clinics, Market Value (USD Million), and CAGR, 2026-2037F
31.2.2. By Treatment Approach
31.2.2.1. Molecular Biological Therapy, Market Value (USD Million), and CAGR, 2026-2037F
31.2.2.2. Steroid Therapy, Market Value (USD Million), and CAGR, 2026-2037F
31.2.2.3. Anti-inflammatory and Immunomodulatory Drugs, Market Value (USD Million), and CAGR, 2026-2037F
31.2.2.4. Myostatin Inhibitors, Market Value (USD Million), and CAGR, 2026-2037F
31.2.2.5. Cell Biological Therapy, Market Value (USD Million), and CAGR, 2026-2037F
31.2.3. Country Level Analysis, Value (USD Million)
31.2.3.1. China Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
31.2.3.2. India Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
31.2.3.3. South Korea Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
31.2.3.4. Australia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
31.2.3.5. Indonesia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
31.2.3.6. Malaysia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
31.2.3.7. Vietnam Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
31.2.3.8. Thailand Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
31.2.3.9. Singapore Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
31.2.3.10. New Zeeland Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
31.2.3.11. Rest of Asia Pacific Excluding Japan Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F

32. Latin America Market

32.1. Overview
32.1.1. Market Value (USD Million), Current and Future Projections, 2026-2037
32.1.2. Increment $ Opportunity Assessment, 2026-2037
32.1.3. Year-on-Year Growth Forecast (%)
32.2. Segmentation (USD million), 2026-2037, By
32.2.1. By Drug Class
32.2.1.1. ~Corticosteroids, Market Value (USD Million), and CAGR, 2026-2037F
32.2.1.2. ~Exon-skipping Drugs, Market Value (USD Million), and CAGR, 2026-2037F
32.2.1.3. ~Gene Therapy, Market Value (USD Million), and CAGR, 2026-2037F
32.2.1.4. ~Others, Market Value (USD Million), and CAGR, 2026-2037F
32.2.2. By Distribution Channel
32.2.2.1. Hospital Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
32.2.2.2. Retail Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
32.2.2.3. Online Pharmacy, Market Value (USD Million), and CAGR, 2026-2037F
32.2.2.4. Specialised Clinics, Market Value (USD Million), and CAGR, 2026-2037F
32.2.3. By Treatment Approach
32.2.3.1. Molecular Biological Therapy, Market Value (USD Million), and CAGR, 2026-2037F
32.2.3.2. Steroid Therapy, Market Value (USD Million), and CAGR, 2026-2037F
32.2.3.3. Anti-inflammatory and Immunomodulatory Drugs, Market Value (USD Million), and CAGR, 2026-2037F
32.2.3.4. Myostatin Inhibitors, Market Value (USD Million), and CAGR, 2026-2037F
32.2.3.5. Cell Biological Therapy, Market Value (USD Million), and CAGR, 2026-2037F
32.2.4. Country Level Analysis, Value (USD Million)
32.2.4.1. Brazil Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
32.2.4.2. Argentina Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
32.2.4.3. Mexico Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
32.2.4.4. Rest of Latin America Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F

33. Middle East & Africa Market

33.1. Overview
33.1.1. Market Value (USD Million), Current and Future Projections, 2026-2037
33.1.2. Increment $ Opportunity Assessment, 2026-2037
33.1.3. Year-on-Year Growth Forecast (%)
33.2. Segmentation (USD million), 2026-2037, By
33.2.1. By Drug Class
33.2.1.1. ~Corticosteroids, Market Value (USD Million), and CAGR, 2026-2037F
33.2.1.2. ~Exon-skipping Drugs, Market Value (USD Million), and CAGR, 2026-2037F
33.2.1.3. ~Gene Therapy, Market Value (USD Million), and CAGR, 2026-2037F
33.2.1.4. ~Others, Market Value (USD Million), and CAGR, 2026-2037F
33.2.2. By Treatment Approach
33.2.2.1. Molecular Biological Therapy, Market Value (USD Million), and CAGR, 2026-2037F
33.2.2.2. Steroid Therapy, Market Value (USD Million), and CAGR, 2026-2037F
33.2.2.3. Anti-inflammatory and Immunomodulatory Drugs, Market Value (USD Million), and CAGR, 2026-2037F
33.2.2.4. Myostatin Inhibitors, Market Value (USD Million), and CAGR, 2026-2037F
33.2.2.5. Cell Biological Therapy, Market Value (USD Million), and CAGR, 2026-2037F
33.2.3. Country Level Analysis, Value (USD Million)
33.2.3.1. Saudi Arabia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
33.2.3.2. UAE Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
33.2.3.3. Israel Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
33.2.3.4. Qatar Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
33.2.3.5. Kuwait Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
33.2.3.6. Oman Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
33.2.3.7. South Africa Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F
33.2.3.8. Rest of Middle East & Africa Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2026-2037F

34. Global Economic Scenario

34.1. World Economic Outlook

35. About the Analyst

35.1. Global Clientele
35.2. Clients Served Across World

Companies Mentioned

Sarepta Therapeutics
PTC Therapeutics
Pfizer
BioMarin
Bristol-Myers Squibb
Eli Lilly and Company
Santhera Pharmaceuticals
NS Pharma
Aurobindo Pharma
Capricor Therapeutics
Catalyst Pharmaceuticals
Italfarmaco
Summit Therapeutics
Catbasis Pharmaceuticals
CureDuchenne

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4939EUR$5,550USD£4,289GBP
Hard Copy	A printed copy of the product will be shipped to you.		€5829EUR$6,550USD£5,061GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5829EUR$6,550USD£5,061GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€9388EUR$10,550USD£8,152GBP

Report Scope

Table of Contents

Companies Mentioned

Related Topics

Related Reports

Duchenne Muscular Dystrophy Drugs Global Market Report 2025

Duchenne Muscular Dystrophy Market Report 2025

Duchenne Muscular Dystrophy Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Nucleic Acid Based Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Duchenne Muscular Dystrophy Drugs - Global Strategic Business Report